Literature DB >> 17680622

Inflammatory biomarkers are not predictive of intermediate-term risk of ventricular tachyarrhythmias in stable CHF patients.

Yuval Konstantino1, Jairo Kusniec, Tamar Reshef, Ofer David-Zadeh, Alexander Mazur, Boris Strasberg, Alexander Battler, Moti Haim.   

Abstract

BACKGROUND: Elevated levels of inflammatory biomarkers and brain natriuretic peptide (BNP) are associated with increased mortality in patients with heart failure (HF). HYPOTHESIS: : The aim of the current study was to assess the correlation between circulating biomarkers and ventricular tachyarrhythmias among patients with HF.
METHODS: Blood samples from 50 stable ambulatory HF patients with moderate to severe systolic left ventricular (LV) dysfunction and an implantable cardioverter defibrillator (ICD) were analyzed for interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), high-sensitivity C-reactive protein (hsCRP) and BNP. Thereafter, the patients were followed for a mean period of 152 +/- 44 days, during which ventricular tachyarrhythmias were recorded by the ICDs.
RESULTS: Follow-up data were obtained from 47 patients. Of them, 45 (96%) had ischemic cardiomyopathy, 38 (81%) had New York Heart Association class I-II, 43 (91%) were males, and the mean age was 68.6 +/- 11.1 years. During follow-up, 5 patients (11%) had nonsustained ventricular tachycardia (NSVT), 6 patients (13%) had sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) and 36 patients (76%) had no events. The circulating biomarkers' levels upon enrollment were not significantly different between patients who subsequently had NSVT or VT/VF and patients who were free of events.
CONCLUSIONS: No correlation was found between plasma levels of IL-6, TNF-alpha, hsCRP and BNP and ventricular arrhythmic events among stable HF patients during an intermediate term follow-up of 5.1 months. Further studies are still required to assess the association between these biomarkers and long-term risk of ventricular tachyarrhythmia. (c) 2007 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17680622      PMCID: PMC6653552          DOI: 10.1002/clc.20110

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  25 in total

1.  Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Comparison with other potential predictors of prognosis.

Authors:  R Kell; A Haunstetter; T J Dengler; C Zugck; W Kübler; M Haass
Journal:  Eur Heart J       Date:  2002-01       Impact factor: 29.983

Review 2.  Inflammatory mediators and the failing heart: past, present, and the foreseeable future.

Authors:  Douglas L Mann
Journal:  Circ Res       Date:  2002-11-29       Impact factor: 17.367

Review 3.  Cytokines and heart failure.

Authors:  W J Paulus
Journal:  Heart Fail Monit       Date:  2000

Review 4.  Immunomodulating therapy: new treatment modality in congestive heart failure.

Authors:  Pål Aukrust; Jan Kristian Damås; Lars Gullestad
Journal:  Congest Heart Fail       Date:  2003 Mar-Apr

5.  C-reactive protein as a predictor of improvement and readmission in heart failure.

Authors:  J L Alonso-Martínez; B Llorente-Diez; M Echegaray-Agara; F Olaz-Preciado; M Urbieta-Echezarreta; C González-Arencibia
Journal:  Eur J Heart Fail       Date:  2002-06       Impact factor: 15.534

6.  Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).

Authors:  A Deswal; N J Petersen; A M Feldman; J B Young; B G White; D L Mann
Journal:  Circulation       Date:  2001-04-24       Impact factor: 29.690

7.  High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure.

Authors:  K Maeda; T Tsutamoto; A Wada; N Mabuchi; M Hayashi; T Tsutsui; M Ohnishi; M Sawaki; M Fujii; T Matsumoto; M Kinoshita
Journal:  J Am Coll Cardiol       Date:  2000-11-01       Impact factor: 24.094

8.  Plasma cytokine parameters and mortality in patients with chronic heart failure.

Authors:  M Rauchhaus; W Doehner; D P Francis; C Davos; M Kemp; C Liebenthal; J Niebauer; J Hooper; H D Volk; A J Coats; S D Anker
Journal:  Circulation       Date:  2000-12-19       Impact factor: 29.690

Review 9.  Arrhythmias in heart failure: current concepts of mechanisms and therapy.

Authors:  L Eckardt; W Haverkamp; R Johna; D Böcker; M C Deng; G Breithardt; M Borggrefe
Journal:  J Cardiovasc Electrophysiol       Date:  2000-01

10.  B-type natriuretic peptide predicts sudden death in patients with chronic heart failure.

Authors:  Rudolf Berger; Martin Huelsman; Karin Strecker; Anja Bojic; Petra Moser; Brigitte Stanek; Richard Pacher
Journal:  Circulation       Date:  2002-05-21       Impact factor: 29.690

View more
  4 in total

1.  Predictors of ventricular arrhythmias in patients with mitral valve prolapse.

Authors:  Yasin Turker; Mehmet Ozaydin; Gurkan Acar; Mustafa Ozgul; Yesim Hoscan; Ercan Varol; Abdullah Dogan; Dogan Erdogan; Habil Yucel
Journal:  Int J Cardiovasc Imaging       Date:  2009-10-22       Impact factor: 2.357

2.  C-reactive protein in arrhythmogenic right ventricular dysplasia/cardiomyopathy and relationship with ventricular tachycardia.

Authors:  Aimé Bonny; Nicolas Lellouche; Ivo Ditah; Françoise Hidden-Lucet; Martial T Yitemben; Benjamin Granger; Fabrice Larrazet; Robert Frank; Guy Fontaine
Journal:  Cardiol Res Pract       Date:  2010-08-24       Impact factor: 1.866

3.  C-reactive protein levels in the brugada syndrome.

Authors:  Aimé Bonny; Joelci Tonet; Manlio F Márquez; Antonio De Sisti; Abdou Temfemo; Caroline Himbert; Fatima Gueffaf; Fabrice Larrazet; Ivo Ditah; Robert Frank; Françoise Hidden-Lucet; Guy Fontaine
Journal:  Cardiol Res Pract       Date:  2011-11-29       Impact factor: 1.866

Review 4.  Classic and Novel Biomarkers as Potential Predictors of Ventricular Arrhythmias and Sudden Cardiac Death.

Authors:  Zornitsa Shomanova; Bernhard Ohnewein; Christiane Schernthaner; Killian Höfer; Christian A Pogoda; Gerrit Frommeyer; Bernhard Wernly; Mathias C Brandt; Anna-Maria Dieplinger; Holger Reinecke; Uta C Hoppe; Bernhard Strohmer; Rudin Pistulli; Lukas J Motloch
Journal:  J Clin Med       Date:  2020-02-20       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.